Table 1.
Clinical, surgical, pathological and inflammatory parameters for the study population
| N (%) or mean ± SD or median (range) | |
|---|---|
| Males | 268 (81.3%) |
| Age (years) | 62.9 ± 8.7 |
| Smoker | 205 (76.5%) |
| Diabetes mellitus | 57 (21.3%) |
| Ischaemic cardiomyopathy | 33 (12.3%) |
| COPD | 100 (37.3%) |
| Hypertension | 103 (38.4%) |
| Dyslipidaemia | 99 (36.9%) |
| Surgical procedure | |
| Lobectomy | 224 (83.6%) |
| Pneumonectomy | 14 (5.2%) |
| Sub-lobar resection | 38 (11.2%) |
| Pathologic stage | |
| Ia/Ib | 173 (64.5%) |
| IIa/IIb | 74 (27.6%) |
| IIIa/IIIb | 19 (7.1%) |
| IV | 2 (0.8%) |
| Histological type | |
| Adenocarcinoma | 168 (62.7%) |
| Squamous cell carcinoma | 79 (29.5%) |
| Large cell carcinoma | 18 (6.7%) |
| Other | 3 (1.1%) |
| Neutrophils, × 109/L | 4.47 (1.63) |
| Lymphocytes, × 109/L | 2.14 (1.59) |
| Monocytes, × 109/L | 0.57 (0.20) |
| Platelets, × 109/L | 243 (79.71) |
| LMR | 3.97 (1.97) |
| NLR | 2.38 (1.23) |
| PLR | 131.59 (65.03) |
COPD chronic obstructive pulmonary disease, LMR lymphocyte-to-monocyte ratio, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio